A radioactive probe 99m Tc-HYNIC-mAb Kv 1.3 Synthesis method and application of

By developing the radioactive probe 99mTc-HYNIC-mAbKv1.3, monoclonal antibodies against the 1.3 channel of the anti-voltage-gated potassium channel are combined with nuclides, which solves the problem of lack of revealing the inflammatory activity of immune cells after myocardial infarction in the living state in the clinical state. , which has achieved clear imaging and evaluation of inflammatory activities after myocardial infarction, and improved the formulation of treatment plans and patient prognosis.

CN117402240BActive Publication Date: 2024-11-29XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202311277356.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-27
Publication Date
2024-11-29
Estimated Expiration
2043-09-27

AI Technical Summary

Technical Problem

Clinical lack of suitable targets and probes reveals the inflammatory activity of immune cells after myocardial infarction in a live state, affecting the treatment and prognosis after myocardial infarction.

Method used

A radioactive probe 99mTc-HYNIC-mAbKv1.3 was developed to connect the monoclonal antibody mAbKv1.3 of the anti-voltage-gated potassium channel 1.3 channel to HYNIC and chelate with nuclide 99mTc for SPECT/CT imaging display. Inflammatory activity in the infarction area after myocardial infarction.

Benefits of technology

The probe can clearly display the inflammation site and the degree of inflammatory damage in the infarction area after myocardial infarction, providing a more objective assessment of inflammatory activity, helping to develop treatment plans and improve patient outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117402240B_ABST
    Figure CN117402240B_ABST
Patent Text Reader

Abstract

The present invention provides a radioactive probe 99m Tc‑HYNIC‑mAb Kv1.3 The synthesis method relates to the technical field of myocardial infarction radionuclide imaging. 99m Tc‑HYNIC‑mAb Kv1.3 The synthesis method of mAb comprises the following steps: S1. Kv1.3 Production of monoclonal antibodies and immunohistochemical staining; S2. Radioactive probes 99m Tc‑HYNIC‑mAb Kv1.3 The present invention provides a method based on mAb Kv1.3 The synthesis method of radioactive probes targets Kv1.3 and designs probes, which use imaging methods to track the activities of immune cells at different stages after myocardial infarction in vivo. This can reflect the degree of inflammatory activity after infarction, the area of ​​inflammatory activity, and the inflammatory activity during the repair period. It is of great significance in assisting clinical non-invasive examinations, formulating treatment plans, and guiding patient prognosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of myocardial infarction nuclide imaging, and in particular to a radioactive probe 99m Tc-HYNIC-mAb Kv 1.3 Synthesis methods and applications. Background Art

[0002] Myocardial infarction is a clinically serious disease with high morbidity and mortality. It occurs due to acute stenosis or occlusion of the coronary arteries, leading to severe myocardial ischemia, hypoxia and necrosis. Patients after myocardial infarction often suffer from irreversible ventricular remodeling, leading to arrhythmias and heart failure, and even death.

[0003] After myocardial infarction, necrotic myocardial cells trigger an inflammatory response, and a large number of immune cells (mainly monocytes / macrophages, neutrophils, lymphocytes, etc.) infiltrate the infarction site. Immune cells have a bidirectional regulatory effect. They participate in the clearance of early necrotic cell fragments after myocardial infarction, inflammatory damage and scar formation during the repair period by regulating their own number and phenotype, mediating ventricular remodeling after myocardial infarction. 0-3 days after myocardial infarction (inflammatory period), monocyte-derived macrophages (mainly M1 type), neutrophils, CD8 + A large number of T lymphocytes and other cells infiltrate the infarct area, clear and phagocytose necrotic cells, and aggravate myocardial injury and apoptosis of myocardial cells by releasing proinflammatory factors and chemokines, thereby promoting ventricular remodeling; 3-7 days after myocardial infarction, the inflammatory response gradually subsides, neutrophils are phagocytosed and decomposed by macrophages, and M1 macrophages gradually change from proinflammatory to anti-inflammatory and repair macrophages (M2); 7-14 days after myocardial infarction, M2 macrophages secrete a large amount of growth factors, which promote fibroblast proliferation, collagen synthesis and deposition, and promote extracellular matrix reconstruction and angiogenesis. A small number of regulatory T cells (Treg cells) also participate in the repair of damaged tissues. Studies have found that in the inflammatory period after myocardial infarction, excessive infiltration of M1 macrophages, neutrophils, etc. can aggravate myocardial damage, expand the infarct area, and aggravate ventricular remodeling, while inhibiting proinflammatory immune cells during this period can effectively improve ventricular remodeling; in the repair period after myocardial infarction, promoting the polarization of M2 macrophages can repair and rebuild necrotic tissue, reduce the infarct area, and improve ventricular remodeling, while the loss of this type of cells will aggravate ventricular remodeling. Therefore, the infiltration degree and activity state of immune cells are closely related to the size of the infarct area and the degree of ventricular remodeling. At different periods after myocardial infarction, observing the infiltration degree and activity state of immune cells in vivo can help clinically implement appropriate treatment methods, reduce ventricular remodeling, and improve patient prognosis. At present, there is a lack of suitable targets and probes in the clinic to reveal the inflammatory activity of immune cells after myocardial infarction in vivo.

[0004] Voltage-gated potassium channel 1.3 (hereinafter referred to as Kv1.3) is a channel protein that can sense voltage changes and mediate the transmembrane outflow of potassium ions. The channel protein is encoded by the KCNA3 gene and is a homotetramer formed by non-covalent binding of subunits of approximately 500 amino acids, including four groups of protein subunits composed of six α-helices that span the membrane six times to form a single-pore channel. The gating of Kv1.3 is controlled by the membrane potential, and changes in membrane potential can be sensed by the "voltage sensor" region containing positive charges. When the cell is activated and the membrane potential is higher than -40mv, the channel opens, allowing potassium ions to flow out of the membrane, increasing the negative value of the membrane potential, and increasing the transmembrane potential difference to form a relative hyperpolarized potential. Following the potential difference, calcium ions flow into the cell, resulting in an increase in the intracellular calcium ion concentration. Calcium ions are important second messengers that can activate subsequent signals and further activate the cell. It can be seen that the Kv1.3 channel is closely related to the activation and activity state of the cell. Kv1.3 channels are expressed in large quantities in immune cells, such as monocytes / macrophages, lymphocytes, neutrophils, etc., but not in myocardial cells. Therefore, using Kv1.3 as a target and designing probes, using imaging methods to track the activity of immune cells at different stages after myocardial infarction in vivo can reflect the degree of post-infarction inflammatory activity, the area of ​​inflammatory activity, and the inflammatory activity during the repair period, which is of great significance in assisting clinical non-invasive examinations, formulating treatment plans, and guiding patient prognosis.

[0005] The applicant previously developed a mouse anti-Kv1.3 channel monoclonal antibody (mAb) based on the extracellular cyclic peptide E314 of the human Kv1.3 channel. Kv1.3 ), has been granted a national invention patent (patent number: ZL201610325161.7). This monoclonal antibody has the characteristics of strong affinity and high specificity, and can specifically recognize human and mouse Kv1.3 channel proteins. In vivo experiments show that it is highly safe and does not affect blood counts, biochemical indicators and organ functions after intravenous injection. Based on the above research foundation, the applicant will mAb Kv1.3 Connect with HYNIC and then with nuclide 99m Tc chelation, purification and radioactive probe 99m Tc-HYNIC-mAb Kv 1.3 By injecting the probe in vivo, SPECT / CT imaging can clearly show the site of inflammation and the degree of inflammatory damage in the infarct area after myocardial infarction in mice, guiding clinical diagnosis and treatment as well as prognosis, to solve the problem of lack of suitable targets and probes in the clinic, and reveal the inflammatory activity of immune cells after myocardial infarction in vivo. Summary of the invention

[0006] 1. Technical issues to be resolved

[0007] In view of the shortcomings of the prior art, the present invention provides a radioactive probe 99m Tc-HYNIC-mAb Kv 1.3 The synthesis method solves the problem that there is currently a lack of suitable targets and probes in clinical practice to reveal the inflammatory activity of immune cells after myocardial infarction in vivo.

[0008] (II) Technical solution

[0009] To achieve the above objectives, the present invention is implemented through the following technical solutions: a radioactive probe 99m Tc-HYNIC-mAb Kv 1.3 The synthesis method specifically comprises the following steps:

[0010] S1.mAb Kv 1.3 Monoclonal antibody production and immunohistochemical staining

[0011] mAbs Kv1.3 The production of monoclonal antibodies is carried out by inoculating the hybridoma cell line AbM-F14FTSSCLS0167-KLH#15 into the peritoneal cavity of mice to obtain ascites containing monoclonal antibodies, and purifying mAbs from the ascites by affinity chromatography. Kv 1.3 Monoclonal antibodies;

[0012] S2. Radioactive probe 99m Tc-HYN IC-mAb Kv 1.3 Synthesis

[0013] mAb Kv 1.3 Antibody purification, mAb Kv 1.3 Antibodies linked to HYNIC, HYNIC-mAb Kv 1.3 Purification, HYN IC-mAb Kv 1.3 Chelation 99m Tc, 99m Tc-HYNIC-mAb Kv 1.3 Labeling rate determination, 99m Tc-HYNIC-mAb Kv 1.3 purification, 99m Tc-HYNI C-mAb Kv 1.3 The synthesis was carried out by radiochemical purity determination.

[0014] Preferably, the mAb Kv 1.3 The steps of antibody purification include:

[0015] Using the Zeba TM Purification of the mAb using a desalting column Kv 1.3 Monoclonal antibodies;

[0016] Removing the Zeba TM Desalting column bottom plug and top cover;

[0017] Zeba TM Place the desalting column in a 1.5 mL EP tube and centrifuge at 1500 g, 1 min, 4 °C to remove the storage solution; mark the bevel and keep it facing outwards during subsequent centrifugation;

[0018] Take 100 μL of Modification buffer and add it to 900 μL of ultrapure water to prepare 1× Modification buffer;

[0019] To the Zeba TM Add 300 μL of 1× Modification buffer to the desalting column and centrifuge at 1500 g, 1 min, 4 °C, and repeat three times;

[0020] Place the desalting column in a new 1.5 mL EP tube;

[0021] Take 2-3 nmol of mAb Kv1.3 The monoclonal antibody was added to the resin center of the desalting column and centrifuged at 1500g, 2min, 4°C to obtain the purified antibody; if the volume of the antibody solution is less than 70μL, ultrapure water should be added to make it up to 70μL before loading.

[0022] Preferably, the mAb Kv 1.3 The steps of connecting the antibody to HYNIC include:

[0023] In a dark environment, weigh 0.4 mg of HYNIC and dissolve it in 40 μL of DMSO to a concentration of 10 μg / μL;

[0024] According to 1 nmol of antibody, take 4 μL of HYNIC, mix HYNIC with the above purified antibody, place on a constant temperature mixer, and store at 4°C in the dark overnight;

[0025] The volume of DMSO added needs to be less than 5% of the total volume; if the volume of DMSO is too large, the volume of DMSO added to dissolve the HYNIC powder can be appropriately reduced to increase the concentration.

[0026] Preferably, the HYNIC-mAb Kv1.3 The purification steps include:

[0027] Get a new Zeba TM Desalting column to remove free HYNIC in the precursor;

[0028] Removing the Zeba TM Desalting column bottom plug and top cover;

[0029] The Zeba TM Place the desalting column in a 1.5 mL EP tube and centrifuge at 1500 g, 1 min, 4 °C to remove the storage solution. Mark the slope and keep it facing outwards during subsequent centrifugation.

[0030] Take 100 μL of Conjugation buffer and add it to 900 μL of ultrapure water to prepare 1× Conjugation buffer;

[0031] Add 300 μL of 1× Conjugation buffer and centrifuge at 1500 g, 1 min, 4 °C, repeat three times;

[0032] The Zeba TM The desalting column was placed in a new 1.5 mL EP tube;

[0033] Take precursor HYNIC-mAb Kv1.3 The reaction system was added to the center of the desalting column resin and centrifuged at 1500g, 2min, 4℃ to obtain the purified HYNIC-mAb. Kv1.3 Coupling product.

[0034] Preferably, the HYNIC-mAb Kv1.3 Chelation 99m The steps of Tc include:

[0035] Weigh Tricine powder to prepare an ultrapure aqueous solution with a concentration of 100 mg / mL;

[0036] Weigh SnCl 2 ·2H 2 Add the solid particles into a 10 mL centrifuge tube and dissolve them in ultrapure water to make a 7 mg / mL stannous chloride aqueous solution;

[0037] Add 100 μL of Tricine solution and 4 μL of SnCl to the treated HYNIC-antibody. 2 Mix the solution; add 500 μL of pertechnetate solution and mix thoroughly;

[0038] Incubate in room temperature, away from light, and shake on a constant temperature mixer for 30 min to obtain99m Tc-HYNIC-mAb Kv1.3 .

[0039] Preferably, the 99m Tc-HYNIC-mAb Kv1.3 The steps of labeling rate determination include:

[0040] Take the iTLC-SG chromatography paper and cut it into long and thin strips with a width of 1 cm. Keep the iTLC-SG chromatography paper dry and avoid bending it. Put the chromatography paper into an electric hot air drying oven at 60°C for 2 hours to dry it.

[0041] Take the dried iTLC-SG chromatography paper and mark the rough surface of the iTLC-SG chromatography paper 1.5 cm away from the two ends with a 2B pencil and a red marker respectively. The 2B pencil mark is used as the sampling origin, and the red marker mark is used as the development end point.

[0042] Take 2-3 μCi of the room temperature chelation reaction completed without purification 99m Tc-HYNIC-mAb Kv1.3 , spot the sample at the origin of the iTLC-SG chromatography paper; after the water marks at the spot are naturally dried, place it in 400 μL of PBS developing agent with the origin facing downward;

[0043] When the developing agent on the iTLC-SG chromatography paper is observed to move to the end point, the iTLC-SG chromatography paper is taken out from the developing agent, allowed to dry naturally, and placed in a radioactive chromatography scanner. The radionuclide is set to 99m Tc, the step size was 1 mm / s, and the radiolabeling rate was calculated based on the peak area.

[0044] Preferably, the 99m Tc-HYNIC-mAb Kv1.3 The purification steps include:

[0045] Open the upper cover of the PD-10 column, cut off the lower outlet, place the PD-10 column vertically, let the preservation solution in the column flow out, and discard the liquid;

[0046] Fill the upper chamber of the PD-10 column with PBS until the liquid flows out; repeat 4 times and discard the outflow liquid;

[0047] Place the PD-10 column in a fume hood; 99m Tc-HYNI C-mAb Kv1.3 The reactants were added to the PD-10 column, and after the sample completely entered the column and no liquid flowed out, the column was filled up to 2.5 mL with PBS;

[0048] Use a numbered 1.5 mL EP tube to collect the outflow liquid, add 500 μL of PBS each time, connect 7 tubes in total, measure the radioactivity of each tube; collect the liquid with the highest radioactivity, which is the purified labeled antibody.

[0049] Preferably, the 99m Tc-HYNI C-mAb Kv1.3 The steps for radiochemical purity determination include:

[0050] Take iTLC-SG chromatography paper and cut it into long and thin strips with a width of 1 cm; keep the chromatography paper dry and avoid bending it during the whole process; put the chromatography paper into an electric hot air drying oven in advance, dry it at 60°C for 2 hours;

[0051] Take the dried iTLC-SG chromatography paper and mark the rough surface of the chromatography paper 1.5 cm away from the two ends with a 2B pencil and a red marker respectively. The 2B pencil mark is used as the sampling origin, and the red marker mark is used as the development end point.

[0052] Take 2-3μCi 99m Tc-HYNIC-mAb Kv1.3 Spot the sample at the origin of the chromatography paper; after the water marks at the spot are naturally dried, place it in 400 μL of PBS or 100% acetone developer with the origin facing downwards;

[0053] When the developing agent on the iTLC-SG chromatography paper is observed to move to the end point, the iTLC-SG chromatography paper is taken out from the developing agent, allowed to dry naturally, and placed in a radioactive chromatography scanner. The radionuclide is set to 99m Tc, the step size was 1 mm / s, and the radiolabeling rate was calculated based on the peak area.

[0054] Preferably, including 99m Tc-HYNIC-mAb Kv 1.3 Probes for SPECT / CT imaging and myocardial infarction in mice 99m Tc-HYN IC-mAb Kv1.3 Biodistribution of probe mice:

[0055] Said 99m Tc-HYN IC-mAb Kv 1.3 SPECT / CT imaging of the probe in the mouse myocardial infarction model is achieved by establishing a mouse myocardial infarction model, injecting the radioactive probe, anesthetizing and imaging.

[0056] Said 99m Tc-HYN IC-mAb Kv1.3The biodistribution of probe mice is as follows: for the mice in the above experimental group and control group, after 24h imaging, they were euthanized, and then plastic test tubes were prepared, marked according to "group, number, organ name", and the mass of the empty tubes was weighed using an electronic balance, and then the mouse eyeballs were removed, and 0.5-1mL of peripheral blood was taken; the mice were dissected and the tissues and organs of interest were taken out, including the brain, heart (non-infarction area), lungs, liver, spleen, kidneys, stomach, pancreas, small intestine, large intestine, muscle, femur, tail, heart (infarction area) and modeling wounds, and the surface and excess blood inside were washed with PBS. Excess water was absorbed with gauze, placed in the bottom of the corresponding marked plastic test tube, weighed and recorded with an electronic balance, and finally the radioactive counts of tissues and organs in each tube were measured using a fully automatic gamma counter, and the percentage of the total amount of injected drug per gram of tissue was calculated after attenuation correction.

[0057] (III) Beneficial effects

[0058] The present invention provides a radioactive probe 99m Tc-HYNIC-mAb Kv 1.3 A synthetic method of a synthetic method.

[0059] It has the following beneficial effects:

[0060] 1. The present invention provides a radioactive probe 99m Tc-HYNIC-mAb Kv 1.3 According to the existing literature reports, by tracing a single immune cell (such as neutrophils or lymphocytes) to evaluate the inflammation of the myocardial infarction area after myocardial infarction, the present invention 99m Tc-HYNIC-mAb Kv 1.3 The probe is the world's first inflammatory cell tracing probe targeting the Kv1.3 channel. It can reflect the common inflammatory activities of various immune cells (monocytes / macrophages, neutrophils, lymphocytes, etc.) in the infarction site after myocardial infarction, and can more objectively and comprehensively evaluate the degree, area and location of inflammatory damage in the infarction area.

[0061] 2. The present invention provides a radioactive probe 99m Tc-HYNIC-mAb Kv 1.3 The synthesis method of the invention is currently used in clinical testing technology for evaluating the area of ​​myocardial infarction, such as 18F-FDG probe PET imaging, which is used to image the viable myocardium after myocardial infarction, but cannot detect the area and degree of inflammatory activity in the infarct area. 99m Tc-HYNIC-mAb Kv 1.3 The probe targets inflammatory tissue in the infarcted area, complementing existing technologies.

[0062] 3. The present invention provides a radioactive probe99m Tc-HYNIC-mAb Kv 1.3 The synthesis method of the prior art, such as: 18F-FDG probe PET imaging, is mainly used for imaging viable myocardium after myocardial infarction, and is mainly used for early evaluation after myocardial infarction. 99m Tc-HYNIC-mAb Kv 1.3 The probe can not only evaluate inflammatory activity in the early stage after myocardial infarction, but also evaluate the repair activity of immune cells during the repair period of myocardial infarction, and has a wider time window for clinical application. BRIEF DESCRIPTION OF THE DRAWINGS

[0063] Figure 1 The mAb was applied to the myocardial infarction area and non-infarction area of ​​the mouse 2-3 days after myocardial infarction surgery. Kv 1.3 Shows Kv1.3 and F4 / 80 immunofluorescence staining images;

[0064] Figure 2 The radioactive probe of the present invention 99m Tc-HYNIC-mAb Kv 1.3 After synthesis, it was incubated with fetal bovine serum, and the instantaneous thin layer chromatography analysis chart group was performed before purification by PD-10 column, 10 minutes after purification, 1 hour after purification, 6 hours after purification, 12 hours after purification, and 24 hours after purification;

[0065] Figure 3 The mice were injected with radioactive probe into the tail vein 2-3 days after myocardial infarction (MI group). 99m Tc-HYNIC-mAb Kv 1.3 Afterwards, SPECT / CT scans were performed in transverse, coronal, and sagittal planes at 1h, 6h, 12h, and 24h, respectively;

[0066] Figure 4 The mice were injected with radioactive probe into the tail vein 2-3 days after sham operation of myocardial infarction (Sham group). 99m Tc-HYNIC-mAb Kv 1.3 Afterwards, SPECT / CT scans were performed in transverse, coronal, and sagittal planes at 1h, 6h, 12h, and 24h, respectively;

[0067] Figure 5 This is a statistical analysis chart of MI / Bl values ​​of myocardial infarction site in the myocardial infarction group (MI) and the sham operation group (Sham) 2-3 days after myocardial infarction by SPECT / CT scan 1, 6, 12, 24 hours later;

[0068] Figure 6It is a statistical analysis chart of MI / Mu values ​​of myocardial infarction site in the myocardial infarction group (MI) and the sham operation group (Sham) 2-3 days after myocardial infarction by SPECT / CT scanning 1, 6, 12, and 24 hours later;

[0069] Figure 7 The mice of the present invention were injected with radioactive probe into the tail vein 9-10 days after myocardial infarction (MI group). 99m Tc-HYNIC-mAb Kv 1.3 Afterwards, SPECT / CT scans were performed in transverse, coronal, and sagittal planes at 1h, 6h, 12h, and 24h, respectively;

[0070] Figure 8 The mice were injected with radioactive probe into the tail vein 9-10 days after sham operation of myocardial infarction (Sham group). 99m Tc-HYNIC-mAb Kv 1.3 Afterwards, SPECT / CT scans were performed in transverse, coronal, and sagittal planes at 1h, 6h, 12h, and 24h, respectively;

[0071] Fig. 9 This is a statistical analysis chart of MI / Bl values ​​of myocardial infarction site in the myocardial infarction group (MI) and the sham operation group (Sham) 9-10 days after myocardial infarction, 1, 6, 12, 24 hours after SPECT / CT scanning;

[0072] Fig.10 It is a statistical analysis chart of MI / Mu values ​​of myocardial infarction site in the myocardial infarction group (MI) and the sham operation group (Sham) 9-10 days after myocardial infarction by SPECT / CT scanning 1, 6, 12, and 24 hours later;

[0073] Fig.11 The myocardial infarction group (MI) and the sham operation group (Sham) were scanned by SPECT / CT for 24 hours and various organ tissues (blood, brain, lung, liver, spleen, kidney, stomach, pancreas, small intestine, large intestine, muscle, bone, non-infarcted myocardium, infarcted myocardium) were collected for detection. 99m Tc-HYN IC-mAb Kv 1.3 Biodistribution map of

[0074] Fig.12 The radioactive probe 68Ga-NOTA-mAb was injected into the tail vein of healthy C57 mice of the present invention. Kv 1.3 Afterwards, PET / CT scans were performed in the coronal and sagittal planes at 1 and 2 hours respectively;

[0075] Fig.13After PET / CT scanning of healthy C57 mice for 2 hours, various organ tissues (blood, brain, heart, lung, liver, spleen, kidney, stomach, small intestine, large intestine, muscle, and bone) were collected to detect 68Ga-NOTA-mAb. Kv 1.3 Biodistribution map.

[0076] Fig.14 The radioactive probe 177Lu-DOTA-mAb of the present invention Kv 1.3 After synthesis, the instantaneous thin layer chromatography analysis chart group was performed before purification on the PD-10 column, and in the 3rd and 8th tubes after purification. DETAILED DESCRIPTION

[0077] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0078] Example:

[0079] like Figure 1-14 As shown, the embodiment of the present invention provides a radioactive probe 99m Tc-HYNIC-mAb Kv 1.3 The synthesis method specifically comprises the following steps:

[0080] S1.mAb Kv 1.3 Monoclonal antibody production and immunohistochemical staining

[0081] mAbs Kv 1.3 The production of monoclonal antibodies is based on the method disclosed in the existing patent "Monoclonal Antibodies Against Extracellular Cyclic Peptide Segments of Voltage-gated Potassium Channel 1.3 and Applications" (Publication No.: CN105968199A), that is, hybridoma cell line AbM-F14FTSSCLS0167-KLH#15 is inoculated into the peritoneal cavity of mice to obtain ascites containing monoclonal antibodies, and monoclonal antibodies mAbs are purified from the ascites by affinity chromatography. Kv 1.3 .

[0082] The mAb obtained Kv1.3 Immunohistochemical staining of the hearts of mice with myocardial infarction was performed to observe the expression of the antibody in the myocardial infarction area and the non-myocardial infarction area. The results showed that the expression of Kv1.3 channels in the myocardial infarction area was significantly higher than that in the non-infarction area. (See Figure 1 );

[0083] S2. Radioactive probe 99m Tc-HYNIC-mAb Kv1.3 Synthesis

[0084] mAb Kv1.3 Antibody purification, mAb Kv1.3 Antibody linked to HYNIC, HYNIC-mAb Kv1.3 Purification, HYNIC-mAb Kv1.3 Chelation 99m Tc, 99m Tc-HYNIC-mAb Kv1.3 Labeling rate determination, 99m Tc-HYNIC-mAb Kv1.3 purification, 99m Tc-HYNIC-mAb Kv1.3 The synthesis was carried out by radiochemical purity determination.

[0085] 1. mAb Kv1.3 Antibody purification

[0086] (1) Using Zeba TM Desalting column purified antibody (7kD, 0.5mL; stored at 4°C);

[0087] (2) Remove Zeba TM Desalting column bottom plug and top cover;

[0088] (3) Zeba TM Place the desalting column in a 1.5 mL EP tube and centrifuge at 1500 g, 1 min, 4 °C to remove the storage solution; mark the bevel and keep it facing outwards during subsequent centrifugation;

[0089] (4) Add 100 μL Modification buffer to 900 μL ultrapure water to prepare 1× Modification buffer;

[0090] (5)To Zeba TM Add 300 μL 1× Modification buffer to the desalting column and centrifuge at 1500 g for 1 min at 4 °C for three times;

[0091] (6) Place the desalting column in a new 1.5 mL EP tube;

[0092] (7) Take monoclonal antibody (mAb) Kv1.3)2-3nmol (about 300-450μg) was added to the center of the resin of the desalting column and centrifuged at 1500g, 2min, 4℃ to obtain the purified antibody. If the volume of the antibody solution is less than 70μL, ultrapure water should be added to make it 70μL before loading.

[0093] mAb Kv1.3 Antibodies linked to HYNIC

[0094] (1) Using an electronic balance, weigh 0.4 mg of HYNIC (molecular weight 286.67) and dissolve it in 40 μL DMSO to a concentration of 10 μg / μL in a light-proof environment.

[0095] (2) According to the ratio of 1 nmol antibody to 4 μL (about 140 nmol) HYNIC, HYNIC and the above purified antibody were mixed and placed on a constant temperature mixer at 4°C in the dark overnight.

[0096] (3) Note that to ensure protein activity, the volume of DMSO added needs to be less than 5% of the total volume; if the volume of DMSO is too large, the volume of DMSO added to dissolve the HYNIC powder can be appropriately reduced to increase the concentration.

[0097] HYNIC-mAb Kv1.3 purification

[0098] (1) Get a new Zeba TM Desalting column to remove free HYNIC in the precursor;

[0099] (2) Remove Zeba TM Desalting bottom plug and top cover;

[0100] (3) Place the desalting column in a 1.5 mL EP tube and centrifuge at 1500 g, 1 min, 4 °C to remove the storage solution;

[0101] (4) Mark the inclined surface and keep it facing outward during the subsequent centrifugation process;

[0102] (5) Add 100 μL Conjugation buffer to 900 μL ultrapure water to prepare 1× Conjugation buffer;

[0103] (6) Add 300 μL 1× Conjugation buffer and centrifuge at 1500 g for 1 min at 4°C. Repeat three times.

[0104] (7) Sample loading: Place the desalting column in a new 1.5 mL EP tube;

[0105] (8) Take the precursor (HYNIC-mAb Kv1.3The reaction system was added to the center of the desalting column resin and centrifuged at 1500g, 2min, 4°C to obtain the purified HYNIC-mAb. Kv1.3 Coupling product.

[0106] HYNIC-mAb Kv1.3 Chelation 99m Tc

[0107] (1) Prepare Tricine solution: Use an electronic balance to weigh an appropriate amount of Tricine powder and add it to ultrapure water to prepare a 100 mg / mL solution;

[0108] (2) Prepare stannous chloride (SnCl 2 ) Solution: Use an electronic balance to weigh an appropriate amount of large-particle SnCl 2 ·2H 2 Add O to a 10 mL centrifuge tube and dissolve it in ultrapure water to make a 7 mg / mL solution.

[0109] (3) Carry out the following chelation reaction in a ventilated lead cabinet: add 100 μL Tricine solution (100 mg / mL), 4 μL SnCl 2 The solution (7 mg / mL) was mixed; 500 μL of pertechnetate solution (radioactivity of 15-20 mCi, 555-740 MBq) was added and mixed thoroughly; the mixture was shaken on a thermomixer at room temperature and protected from light for 30 min to obtain 99m Tc-HYNIC-mAb Kv1.3 .

[0110] five, 99m Tc-HYNIC-mAb Kv1.3 Labeling rate determination

[0111] (1) Take iTLC-SG chromatography paper and cut it into long and thin strips with a width of 1 cm; keep the chromatography paper dry and avoid bending it during the whole process; put the chromatography paper into an electric hot air drying oven in advance and dry it at 60°C for 2 hours;

[0112] (2) Take the dried iTLC-SG chromatography paper and mark the rough surface of the chromatography paper 1.5 cm away from the two ends with a 2B pencil and a red marker. The 2B pencil mark is used as the sampling origin, and the red marker mark is used as the development end point;

[0113] (3) Take 74-111KBq (2-3μCi) of the room temperature chelation reaction without purification 99m Tc-HYNIC-mAb Kv1.3, spot the sample at the origin of the iTLC-SG chromatography paper. After the water marks at the spot are naturally dried, place it in 400μL PBS developer with the origin facing downwards, making sure that the spot does not touch the developer.

[0114] (4) When the developing agent on the chromatography paper is observed to move to the end point (the red dot is blurred), the chromatography paper is removed from the developing agent, allowed to dry naturally, and placed in a radioactive tomography scanner. The radionuclide is set to 99m Tc, the step size was 1 mm / s, and the radiolabeling rate was calculated based on the peak area.

[0115] six, 99m Tc-HYNIC-mAb Kv1.3 purification

[0116] Purification using PD-10 desalting chromatography column (referred to as PD-10 column) 99m Tc-HYNIC-mAb Kv1.3 .

[0117] (1) Preparation: Open the upper cap of the PD-10 column and cut off the lower outlet. Place the PD-10 column vertically to allow the preservation solution in the column to drain out and discard the liquid.

[0118] Balance: Fill the upper chamber of the PD-10 column with PBS until the liquid flows out; repeat 4 times and discard the outflow liquid (about 20-25 mL of PBS is used in total);

[0119] (2) Sample addition: Place the PD-10 column in a ventilated lead cabinet; 99m Tc-HYNIC-mAb Kv1.3 The reactants were added to the PD-10 column. After the sample completely entered the column and no liquid flowed out, the column was filled up to 2.5 mL with PBS (PBS volume = 2.5 mL - sample volume);

[0120] (3) Elution: Use a numbered 1.5 mL EP tube to collect the outflow liquid, add 500 μL PBS each time, connect 7 tubes in total, and measure the radioactivity of each tube. Collect the liquid with the highest radioactivity, which is the purified labeled antibody. The product appears in the second or third tube.

[0121] seven, 99m Tc-HYNIC-mAb Kv1.3 Radiochemical purity determination (see Figure 2 )

[0122] (1) Take iTLC-SG chromatography paper and cut it into long and thin strips with a width of 1 cm; keep the chromatography paper dry and avoid bending it during the whole process; put the chromatography paper into an electric hot air drying oven in advance and dry it at 60°C for 2 hours;

[0123] (2) Take the dried iTLC-SG chromatography paper and mark the rough surface of the chromatography paper 1.5 cm away from the two ends with a 2B pencil and a red marker. The 2B pencil mark is used as the sampling origin, and the red marker mark is used as the development end point;

[0124] (3) Take 74–111 KBq (2–3 μCi) of purified 99m Tc-HYNIC-mAb Kv1.3 , spot the sample at the origin of the iTLC-SG chromatography paper. After the water marks at the spot are naturally dried, place it in 400μL PBS developer with the origin facing downwards, making sure that the spot does not touch the developer.

[0125] (4) When the developing agent on the chromatography paper is observed to move to the end point (the red dot is blurred), the chromatography paper is removed from the developing agent, allowed to dry naturally, and placed in a radioactive tomography scanner. The radionuclide is set to 99m Tc, the step size was 1 mm / s, and the radiolabeling rate was calculated based on the peak area;

[0126] S3. 99m Tc-HYNIC-mAb Kv1.3 Probe SPECT / CT imaging in a mouse myocardial infarction model (see Figure 3-10 )

[0127] SPECT / CT imaging is achieved through the establishment of a mouse myocardial infarction model, radioactive probe injection, anesthesia and imaging

[0128] (I) Establishment of myocardial infarction model in mice

[0129] The mouse models were divided into two groups: ① myocardial infarction experimental group (MI) and ② sham operation group (Sham). After weighing, anesthetizing, and skin preparation, the mice in the MI group were fixed on a small animal constant temperature (37℃) operating table, connected to the electrodes of the small animal electrocardiograph, and began to record the changes in the mouse lead II electrocardiogram; oral tracheal intubation was performed and connected to the small animal ventilator; the skin was cut, the muscles were bluntly separated, and the chest was opened at the level of the fourth intercostal space; the heart was exposed, and attention was paid to prevent lung tissue damage. The pericardium was separated under a microscope, and the left anterior descending branch of the coronary artery was found. The 6-0 non-damaging suture was used to ligate about 2mm below the lower edge of the left atrial appendage. It can be seen that the ST segment of the electrocardiogram lead II was significantly elevated, and the ischemic area of ​​the heart turned white; the chest was closed layer by layer, and a needle core cannula was reserved. After closing the chest, the residual gas in the chest cavity was extracted; the skin was sutured, and the respiratory rhythm and amplitude were observed. After stabilization, the mice could be disconnected from the ventilator. Suture ligation was not performed in the operation steps of the Sham group mice, and the remaining steps were the same as those of the MI group.

[0130] (II) Radioactive Probe Injection

[0131] The above two groups of mice: ① Myocardial Infarction experimental group (Myocardial Infarction, MI), ② Sham operation group (Sham), each mouse was injected with about 18.5-37MBq (0.5-1mCi) through the tail vein injection 99m Tc-HYNIC-mAb Kv1.3 (About 150 μL PBS). Record the time of drug extraction and drug activity, the time of drug injection, the activity and time of residual drug, and the weight of the mouse.

[0132] (III) Anesthesia and imaging

[0133] (1) Anesthetize mice with isoflurane gas anesthesia using a small animal gas anesthesia machine. Before imaging, place the animal in an anesthesia induction box. After anesthesia, place the animal in the SPECT / CT animal cabin and keep it in a prone position. Anesthesia is continued during SPECT / CT imaging for about 15-20 minutes. The isoflurane flow rate is set to 1.5 LPM (liters / minute).

[0134] (2) The mice were imaged 1, 6, 12, and 24 hours after injection of the imaging agent. Using a small animal PET / SPECT / CT imaging machine, the CT positioning phase was first acquired, and the scanning range of subsequent CT and SPECT was set to the mouse chest. A CT spiral scan was performed first. The CT scanning parameters were as follows: the scanning protocol was CT_Conventional_Scan, the voltage was 50KV, the current was 0.5mA, the step angle was 1.00°, and the single frame acquisition time was 2000ms. The CT reconstruction parameters were as follows: the reconstruction protocol was CT_FDK_Recon, the image matrix was 512×512, and the filter was soft.

[0135] (3) After the CT scan is completed, the SPECT scan is automatically performed. The SPECT scan parameters are as follows: the nuclide setting and energy preset are 99m Tc, scan SPECT_LargeFOV_Scan, the number of bed steps is determined by the selected area of ​​the positioning phase, the step angle is 3.0, the acquisition time of each frame is 10-15s, and a high detection efficiency collimator is selected. SPECT reconstruction parameters are as follows: reconstruction protocol is SPECT_mice_Recon, algorithm type is OSEM, image matrix is ​​60×60, median filter is selected, and the number of iterations is 40.

[0136] (4) After image acquisition, image post-processing workstation NMSoft-AIWS was used for image processing. SPECT / CT fusion images were obtained, and the region of interest (ROI) on the fusion image was delineated, including the myocardial infarction site, blood pool, liver and muscle tissue, and the above sites were anatomically located according to the CT image. After delineation, the radioactivity count was obtained. The quantitative unit of CT images is the CT value, namely the Hounsfield unit (Hu), and the SPECT image uses the percentage of injected dose per gram-tissue (the percentage of the total amount of injected drug per gram of tissue) as the quantitative unit of radioactivity count of the image and ROI.

[0137] Myocardial Infarction to blood pool ratio (MI / Bl ratio):

[0138] MI / Bl ratio = count 心梗部位 / count 血池 .

[0139] Myocardial Infarction to muscle ratio (MI / Muratio):

[0140] MI / Mu ratio = count 心梗部位 / count 肌肉 .

[0141] S4. 99m Tc-HYNIC-mAb Kv1.3 Biodistribution of probe mice (see Fig.11 )

[0142] (1) All mice in the experimental and control groups were euthanized after 24 hours of imaging.

[0143] (2) Prepare plastic test tubes, label them according to “group, number, and organ name,” and use an electronic balance to weigh the mass of the empty tubes.

[0144] (3) Remove the mouse eyeballs and take 0.5-1 mL of peripheral blood; dissect the mouse and remove the tissues and organs of interest, including the brain, heart (non-obstructed area), lungs, liver, spleen, kidneys, stomach, pancreas, small intestine, large intestine, muscle, femur, tail, heart (obstructed area) and modeling wound. Use PBS to clean the surface and excess blood inside. Use gauze to absorb excess water, put it in the bottom of the corresponding marked plastic test tube, and use an electronic balance to weigh and record the mass.

[0145] (4) Use an automatic gamma counter to measure the radioactivity count of tissues and organs in each tube, and calculate the percentage of the total amount of injected drug per gram of tissue after attenuation correction;

[0146] The present invention is based on the Kv1.3 channel extracellular cyclic peptide E314, which has been authorized as a patent "Monoclonal antibody against voltage-gated potassium channel 1.3 extracellular cyclic peptide and its application" (publication number: CN105968199A). Kv1.3 Connect with HYNIC and then with Nuclide 99m Tc chelation, purification and radioactive probe 99m Tc-HYNIC-mAb Kv1.3 By injecting the probe into mice in vivo, SPECT / CT imaging can clearly show the location of inflammation and the degree of inflammatory damage in the infarct area after myocardial infarction in mice, guiding clinical diagnosis, treatment and prognosis.

[0147] Based on the attached drawings, the following details are given:

[0148] Figure 1 Immunofluorescence staining of Kv1.3 and F4 / 80 in the infarcted and non-infarcted areas of the heart 2-3 days after myocardial infarction surgery in mice. mAb Kv1.3 , anti-mouse F4 / 80 antibodies were used as primary antibodies for Kv1.3 and F4 / 80, respectively. Green fluorescence showed the expression of Kv1.3, red fluorescence showed the expression of F4 / 80, and blue fluorescence DAPI was the cell nucleus. The scale bar is 50μm. Staining showed that the expression of Kv1.3 and F4 / 80 in the myocardial infarction area was significantly higher than that in the non-myocardial infarction area, indicating increased inflammatory cell infiltration.

[0149] Figure 2 Radioactive probe 99m Tc-HYNIC-mAb Kv 1.3 After synthesis, the cells were incubated with fetal bovine serum and transient thin layer chromatography was performed before purification on a PD-10 column, 10 minutes after purification, 1 hour after purification, 6 hours after purification, 12 hours after purification, and 24 hours after purification. The experimental results showed that the radioactive probe 99m Tc-HYNI C-mAb Kv 1.3 Good in vitro stability.

[0150] Figure 3 2-3 days after myocardial infarction, mice (MI group) were injected with radioactive probes through the tail vein 99m Tc-HYNIC-mAb Kv 1.3 After 1h, 6h, 12h, and 24h, SPECT / CT scans were performed in the transverse, coronal, and sagittal planes. The arrows indicate the high signal areas, which are the active inflammatory sites in the infarct area identified by the probe.

[0151] Figure 4 2-3 days after sham operation of myocardial infarction, mice (Sham group) were injected with radioactive probe into the tail vein. 99m Tc-HYNIC-mAb Kv 1.3 SPECT / CT scans were performed at 1h, 6h, 12h, and 24h after the operation. No obvious infarction or inflammatory activity areas were found in the images.

[0152] Figure 5 Statistical analysis of MI / Bl values ​​at the myocardial infarction site in the myocardial infarction group (MI) and the sham operation group (Sham) 2-3 days after myocardial infarction, 1, 6, 12, and 24 hours after SPECT / CT scans. MI group n = 8, Sham group n = 3, *** P<0.001. The figure shows that the MI / Bl values ​​of the MI group at 6, 12, and 24 hours were significantly higher than those of the Sham group.

[0153] Figure 6 Statistical analysis of MI / Mu values ​​at the myocardial infarction site in the myocardial infarction group (MI) and the sham operation group (Sham) 2-3 days after myocardial infarction, 1, 6, 12, and 24 hours after SPECT / CT scans. MI group n = 8, Sham group n = 3, * P<0.05. The figure shows that the MI / Mu value at 12 hours in the MI group was significantly higher than that in the Sham group.

[0154] Figure 7 9-10 days after myocardial infarction, mice (MI group) were injected with radioactive probes through the tail vein 99m Tc-HYNIC-mAb Kv 1.3 After 1h, 6h, 12h, and 24h, SPECT / CT scans were performed in the transverse, coronal, and sagittal planes. The arrows indicate the high signal areas, which are the active inflammatory sites in the infarct area identified by the probe.

[0155] Figure 8 9-10 days after sham operation of myocardial infarction, mice (Sham group) were injected with radioactive probe into the tail vein. 99m Tc-HYNIC-mAb Kv 1.3 SPECT / CT scans were performed at 1h, 6h, 12h, and 24h after the operation. No obvious infarction or inflammatory activity areas were found in the images.

[0156] Fig. 9Statistical analysis of MI / Bl values ​​at the myocardial infarction site in the myocardial infarction group (MI) and the sham operation group (Sham) 9-10 days after myocardial infarction, 1, 6, 12, and 24 hours after SPECT / CT scans. MI group n = 8, Sham group n = 3, ** P<0.01. The figure shows that the MI / Bl values ​​of the MI group at 12 and 24 hours were significantly higher than those of the Sham group.

[0157] Fig.10 Statistical analysis of MI / Mu values ​​at the myocardial infarction site in the myocardial infarction group (MI) and the sham operation group (Sham) 9-10 days after myocardial infarction, 1, 6, 12, and 24 hours after SPECT / CT scans. MI group n = 8, Sham group n = 3, * P<0.5. The figure shows that the 24-hour MI / Mu value in the MI group was significantly higher than that in the Sham group.

[0158] Fig.11 The myocardial infarction group (MI) and the sham operation group (Sham) were scanned with SPECT / CT for 24 hours and various organ tissues (blood, brain, lung, liver, spleen, kidney, stomach, pancreas, small intestine, large intestine, muscle, bone, non-infarcted myocardium, infarcted myocardium) were collected for detection. 99m Tc-HYNI C-mAb Kv 1.3 Biodistribution of MI group n = 6, Sham group n = 3, ** P<0.01. The figure shows that the biodistribution of the probe in the myocardial infarction area of ​​the MI group was significantly higher than that of the Sham group.

[0159] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A radioactive probe 99m Tc-HYNIC-mAb Kv1.3 The application of the synthetic method in the preparation of an imaging agent for revealing the location of inflammation and the degree of inflammatory damage in the infarct area after myocardial infarction, It is characterized in that The synthesis method specifically comprises the following steps: S1.mAb Kv1.3 Monoclonal antibody production and immunohistochemical staining mAbs Kv1.3 The production of monoclonal antibodies is carried out by inoculating the hybridoma cell line AbM-F14FTSSCLS0167-KLH#15 into the peritoneal cavity of mice to obtain ascites containing monoclonal antibodies, and purifying mAbs from the ascites by affinity chromatography. Kv1.3 Monoclonal antibodies; S2. Radioactive probe 99m Tc-HYNIC-mAb Kv1.3 Synthesis mAb Kv1.3 Antibody purification, mAb Kv1.3 Antibody linked to HYNIC, HYNIC-mAb Kv1.3 Purification, HYNIC-mAb Kv1.3 Chelation 99m Tc, 99m Tc-HYNIC-mAb Kv1.3 Labeling rate determination, 99m Tc-HYNIC-mAb Kv1.3 purification, 99m Tc-HYNIC-mAb Kv1.3 Synthesis is accomplished by radiochemical purity determination; The mAb Kv1.3 The steps of antibody purification include: Using Zeba TM Purification of the mAb using a desalting column Kv1.3 Monoclonal antibodies; Removing the Zeba TM Desalting column bottom plug and top cover; Zeba TM Place the desalting column in a 1.5 mL EP tube and centrifuge at 1500 g, 1 min, 4 °C to remove the storage solution; mark the bevel and keep it facing outwards during subsequent centrifugation; Take 100 μL of Modification buffer and add it to 900 μL of ultrapure water to prepare 1× Modification buffer; To the Zeba TM Add 300 μL of 1× Modification buffer to the desalting column and centrifuge at 1500 g, 1 min, 4 °C, and repeat three times; Place the desalting column in a new 1.5 mL EP tube; Take 2-3 nmol of mAb Kv1.3 The monoclonal antibody was added to the resin center of the desalting column and centrifuged at 1500 g, 2 min, 4° C. to obtain the purified antibody.

2. A radioactive probe according to claim 1 99m Tc-HYNIC-mAb Kv1.3 The application of the synthetic method in the preparation of an imaging agent for revealing the location of inflammation and the degree of inflammatory damage in the infarct area after myocardial infarction, Features: The mAb Kv1.3 The steps of connecting the antibody to HYNIC include: In a dark environment, weigh 0.4 mg of HYNIC and dissolve it in 40 μL of DMSO to a concentration of 10 μg / μL; According to 1 nmol of antibody, take 4 μL of HYNIC, mix HYNIC with the above purified antibody, place on a constant temperature mixer, and store at 4°C in the dark overnight; The volume of DMSO added was less than 5% of the total volume.

3. A radioactive probe according to claim 2 99m Tc-HYNIC-mAb Kv1.3 The application of the synthetic method in the preparation of an imaging agent for revealing the location of inflammation and the degree of inflammatory damage in the infarct area after myocardial infarction, Features: The HYNIC-mAb Kv1.3 The purification steps include: Get a new Zeba TM Desalting column to remove free HYNIC in the precursor; Removing the Zeba TM Desalting column bottom plug and top cover; The Zeba TM Place the desalting column in a 1.5 mL EP tube and centrifuge at 1500 g, 1 min, 4 °C to remove the storage solution. Mark the slope and keep it facing outwards during subsequent centrifugation. Take 100 μL of Conjugation buffer and add it to 900 μL of ultrapure water to prepare 1× Conjugation buffer; Add 300 μL of 1× Conjugation buffer and centrifuge at 1500 g, 1 min, 4 °C, repeat three times; The Zeba TM The desalting column was placed in a new 1.5 mL EP tube; Take precursor HYNIC-mAb Kv1.3 The reaction system was added to the center of the desalting column resin and centrifuged at 1500g, 2min, 4℃ to obtain the purified HYNIC-mAb. Kv1.3 Coupling product.

4. A radioactive probe according to claim 3 99m Tc-HYNIC-mAb Kv1.3 The application of the synthetic method in the preparation of an imaging agent for revealing the location of inflammation and the degree of inflammatory damage in the infarct area after myocardial infarction, Features: The HYNIC-mAb Kv1.3 Chelation 99m The steps of Tc include: Weigh Tricine powder to prepare an ultrapure aqueous solution with a concentration of 100 mg / mL; Weigh SnCl 2 ·2H 2 Add the solid particles into a 10 mL centrifuge tube and dissolve them in ultrapure water to make a 7 mg / mL stannous chloride aqueous solution; Add 100 μL of Tricine solution and 4 μL of SnCl to the treated HYNIC-antibody. 2 Mix the solution; add 500 μL of pertechnetate solution and mix thoroughly; Incubate in room temperature, away from light, and shake on a constant temperature mixer for 30 min to obtain 99m Tc-HYNIC-mAb Kv1.3 .

5. A radioactive probe according to claim 4 99m Tc-HYNIC-mAb Kv1.3 The application of the synthetic method in the preparation of an imaging agent for revealing the location of inflammation and the degree of inflammatory damage in the infarct area after myocardial infarction, Features: Said 99m Tc-HYNIC-mAb Kv1.3 The steps of labeling rate determination include: Take the iTLC-SG chromatography paper and cut it into long and thin strips with a width of 1 cm. Keep the iTLC-SG chromatography paper dry and avoid bending it. Put the chromatography paper into an electric hot air drying oven at 60°C for 2 hours to dry it. Take the dried iTLC-SG chromatography paper and mark the rough surface of the iTLC-SG chromatography paper 1.5 cm away from the two ends with a 2B pencil and a red marker respectively. The 2B pencil mark is used as the sampling origin, and the red marker mark is used as the development end point. Take 2-3 μCi of the room temperature chelation reaction completed without purification 99m Tc-HYNIC-mAb Kv1.3 , spot the sample at the origin of the iTLC-SG chromatography paper; after the water marks at the spot are naturally dried, place it in 400 μL of PBS developing agent with the origin facing downward; When the developing agent on the iTLC-SG chromatography paper is observed to move to the end point, the iTLC-SG chromatography paper is taken out from the developing agent, allowed to dry naturally, and placed in a radioactive chromatography scanner. The radionuclide is set to 99m Tc, the step size was 1 mm / s, and the radiolabeling rate was calculated based on the peak area.

6. A radioactive probe according to claim 5 99m Tc-HYNIC-mAb Kv1.3 The application of the synthetic method in the preparation of an imaging agent for revealing the location of inflammation and the degree of inflammatory damage in the infarct area after myocardial infarction, Features: Said 99m Tc-HYNIC-mAb Kv1.3 The purification steps include: Open the upper cover of the PD-10 column, cut off the lower outlet, place the PD-10 column vertically, let the preservation solution in the column flow out, and discard the liquid; Fill the upper chamber of the PD-10 column with PBS until the liquid flows out; repeat 4 times and discard the outflow liquid; Place the PD-10 column in a fume hood; 99m Tc-HYNIC-mAb Kv1.3 The reactants were added to the PD-10 column, and after the sample completely entered the column and no liquid flowed out, the column was filled up to 2.5 mL with PBS; Use a numbered 1.5 mL EP tube to collect the outflow liquid, add 500 μL of PBS each time, connect 7 tubes in total, measure the radioactivity of each tube; collect the liquid with the highest radioactivity, which is the purified labeled antibody.

7. A radioactive probe according to claim 6 99m Tc-HYNIC-mAb Kv1.3 The application of the synthetic method in the preparation of an imaging agent for revealing the location of inflammation and the degree of inflammatory damage in the infarct area after myocardial infarction, Features: Said 99m Tc-HYNIC-mAb Kv1.3 The steps for radiochemical purity determination include: Take iTLC-SG chromatography paper and cut it into long and thin strips with a width of 1 cm; keep the chromatography paper dry and avoid bending it during the whole process; put the chromatography paper into an electric hot air drying oven in advance, dry it at 60°C for 2 hours; Take the dried iTLC-SG chromatography paper and mark the rough surface of the chromatography paper 1.5 cm away from the two ends with a 2B pencil and a red marker respectively. The 2B pencil mark is used as the sampling origin, and the red marker mark is used as the development end point. Take 2-3μCi 99m Tc-HYNIC-mAb Kv1.3 Spot the sample at the origin of the chromatography paper; after the water marks at the spot are naturally dried, place it in 400 μL of PBS or 100% acetone developer with the origin facing downwards; When the developing agent on the iTLC-SG chromatography paper is observed to move to the end point, the iTLC-SG chromatography paper is taken out from the developing agent, allowed to dry naturally, and placed in a radioactive chromatography scanner. The radionuclide is set to 99m Tc, the step size was 1 mm / s, and the radiolabeling rate was calculated based on the peak area.

Citation Information

Patent Citations

  • Monoclonal antibodies against the extracellular cyclic peptide of voltage-gated potassium channel 1.3 and their applications

    CN105968199B

  • Anti-voltage gated potassium channel 1.3 extracellular cyclopeptide fragment monoclonal antibody and application thereof

    CN105968199A

  • Preparation method of nuclide molecular probe targeting CD4 receptor and application of nuclide molecular probe serving as heart transplant rejection reaction imaging agent

    CN111084889A